IL-21 program NIAMS

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameIL-21 program NIAMS
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInterleukin-21 stimulants
TargetsInterleukin-21
Therapy Area/IndicationsRejection of organ transplantationInflammationHypersensitivity +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Arthritis And Musculoskeletal And Skin Diseases
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthNational Institute Of Arthritis And Musculoskeletal And Skin Diseases
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationInflammationHypersensitivity +[5] 

Other Information

ATC CodeN/A
Related LinksN/A